MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes

Diabetologia

Volumn 56, Issue 3, 2013, Pages 663-674

  Zhong, X ^a,b,c   Chung, A C K ^a,b   Chen, H Y ^a,b   Dong, Y ^a   Meng, X M ^a,b   Li, R ^a,b   Yang, W ^b   Hou, F F ^c   Lan, H Y ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; MicroRNA 21; Smad7; TGF signalling

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 21; SHORT HAIRPIN RNA; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GENETIC ASSOCIATION; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE CELL; MALE; MESANGIUM CELL; MICROALBUMINURIA; MOUSE; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA TRANSPORT;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; IN SITU HYBRIDIZATION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; RATS; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878269299     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2804-x     Document Type: Article

References (41)

1. Kanwar YS, Wada J, Sun L et al (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 233:4-11
2. Soldatos G, Cooper ME (2008) Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 82(Suppl 1):S75-S79
3. Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for Tgf-Beta as the major mediator. J Am Soc Nephrol 15(Suppl 1):S55-S57
4. Yaswen L, Kulkarni AB, Fredrickson T et al (1996) Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 87:1439-1445
5. Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the microRNA perspective. Diabetes 60:1832-1837
6. Lan HY (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 7:1056-1067
7. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY (2011) Smad3-mediated upregulation of miR-21 promotes renal fibrosis. Clin J Am Soc Nephrol 22:1668-1681
8. Chung AC, Huang XR, Meng X, Lan HY (2010) miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 21:1317-1325
9. Qin W, Chung AC, Huang XR et al (2011) TGF-{beta}/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. Clin J Am Soc Nephrol 22:1462-1474
10. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M (2012) microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 3:49
11. Chau BN, Xin C, Hartner J et al (2012) MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 4:121ra118
12. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Ren Physiol 301:F793-F801
13. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY (2003) Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 63:2010-2019
14. Chung AC, Zhang H, Kong YZ et al (2010) Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 21:249-260
15. Hou CC, Wang W, Huang XR et al (2005) Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 166:761-771
16. Lan HY, Mu W, Tomita N et al (2003) Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14:1535-1548
17. Ng YY, Hou CC, Wang W, Huang XR, Lan HY (2005) Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl: S83-91
18. Ka SM, Huang XR, Lan HY et al (2007) Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18:1777-1788
19. Kloosterman WP, Wienholds E, de Bruijn E, Kauppinen S, Plasterk RH (2006) In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods 3:27-29
20. Williams MD, Nadler JL (2007) Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7:242-248
21. Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. Clin J Am Soc Nephrol 19:433-442
22. Liu G, Friggeri A, Yang Y et al (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207:1589-1597
23. Wang W, Huang XR, Li AG et al (2005) Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 16:1371-1383
24. Chen H, Huang XR, Wang W et al (2010) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60:590-601
25. Dey N, Das F, Mariappan MM et al (2011) MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem 286:25586-25603
26. Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-984
27. Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY (2009) Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24:1443-1454
28. Roy S, Khanna S, Hussain SR et al (2009) MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 82:21-29
29. Sheedy FJ, Palsson-McDermott E, Hennessy EJ et al (2010) Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 11:141-147
30. Merline R, Moreth K, Beckmann J et al (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 4:ra75
31. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J (2010) Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A 107:14339-14344
32. Fu X, Han Y, Wu Y et al (2011) Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 41:1245-1253
33. Pan X, Wang ZX, Wang R (2011) MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 10:1224-1232
34. Liu PT, Wheelwright M, Teles R et al (2012) MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med 18:267-273
35. Lu TX, Hartner J, Lim EJ et al (2011) MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol 187:3362-3373
36. Roggli E, Britan A, Gattesco S et al (2010) Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59:978-986
37. Zhang Z, Peng H, Chen J et al (2009) MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 583:2009-2014
38. Breyer MD, Bottinger E, Brosius FC 3rd et al (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27-45
39. Cohen MP, Clements RS, Cohen JA, Shearman CW (1996) Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia 39:270-274
40. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH (2009) Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52:1669-1679
41. Arakawa K, Ishihara T, Oku A et al (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578-586